Keros Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer initiated coverage of Keros Therapeutics with an Outperform rating and $102 price target. The firm considers the company’s pipeline one of the more attractive in biotech right now given its disease-modifying potential in indications with considerable unmet need. While myelodysplastic syndrome and myelofibrosis serve as the main near-term value drivers, the market opportunities in pulmonary arterial hypertension and obesity provide meaningful upside potential over the next 12-18 months, the analyst tells investors in a research note.